Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression.

Trial Profile

Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2013

At a glance

  • Drugs Capecitabine (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 25 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 30 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top